Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Catabasis Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Catabasis Pharmaceuticals is drawing on research showing that salicylate, a close relative of aspirin, improves glucose homeostasis in people living with type 2 diabetes. Catabasis hopes that by combining salicylate with optimized forms of omega-3 fatty acids, it can come up with a safe and reimbursable drug that simultaneously inhibits pro-inflammatory pathways and activates anti-inflammatory pathways, with benefits for diabetes, dyslipidemia, and inflammatory diseases.

You may also be interested in...

Diabetes Drug Development: Seeing Light In The Dark Ages?

Tougher regulatory hurdles introduced three years ago extended the timelines for successful diabetes drug development, discouragiing investment and partnering activity. An ever-increasing incidence of diabetes, metabolic disorders, and obesity continues to drive innovation and the development of new medicines – but with less emphasis on novel mechanisms.

Catabasis Uses New Financing To Take Two Programs Forward Simultaneously

The biotech now has the funding to move a second program into the clinic; a program it hopes to carry to approval on its own.

The A-List: 2010's Trend-Shaping Series A Financings

Investments for start-ups seeking their first infusion of venture capital continues to be scarce as venture firms seek later-stage opportunities and liquidity to improve their own chances of raising new funds.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts